Skip to NavigationSkip to content

Nice backs Novartis’ lung cancer drug

Published on 20/05/16 at 09:39am

The National Institute for Health and Care Excellence (Nice) has recommended Novartis’ (VTX: NOVN) Ceritinib (zykadia) as a treatment for lung cancer. 

Ceritinib has marketing authorisation in the UK as a treatment for anaplastic lymphoma kinase (ALK) positive advanced non-small-cell lung cancer (NSCLC). Ceritinib is an ALK inhibitor. 

The company submission stated that the NHS list price is £4,923.45 for a 30-day supply. 

Lung cancer is the third most common cancer in the UK (2013), accounting for 13% of all new cases. It is the second most common cancer in both males (14% of all male cases) and females (12% of all female cases).

In 2013, there were 45,525 new cases of lung cancer in the UK: 24,481 (54%) in males and 21,044 (46%) in females. The crude incidence rate shows that there are 78 new lung cancer cases for every 100,000 males in the UK, and 65 for every 100,000 females.

Anjali Shukla

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches